<DOC>
	<DOCNO>NCT00900276</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood urine patient cancer healthy participant laboratory may help doctor identify learn biomarkers related cancer . PURPOSE : This laboratory study look biomarkers patient kidney cancer cancer urothelium healthy participant .</brief_summary>
	<brief_title>Biomarkers Patients With Kidney Cancer Cancer Urothelium Healthy Participants</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether bone morphogenetic protein antagonist regulate cancer ( BARC ) present urine serum sample patient renal cell carcinoma transitional cell carcinoma urothelium healthy participant whether change BARC expression level fluid correlate various disease state . - Evaluate BARC 's utility biomarker kidney cancer . - Determine whether difference BARC level exist patient cancer vs non-cancer patient visit urology clinic . - Determine whether difference BARC level exist among different type kidney cancer . - Evaluate serum marker iron metabolism determine whether change BARC expression correlate change systemic iron marker . - Determine whether development enzyme-linked immunosorbent assay detect BARC level diagnostic procedure feasible desirable . OUTLINE : This pilot study . Blood urine sample collect . Samples evaluate immunoblotting detect bone morphogenetic protein antagonist regulate cancer ( BARC ) mass spectrometry analysis detect hepcidin level . Serum sample analyze serum iron , ferritin , total-iron body capacity . Histology biopsy sample record patient undergo nephrectomy renal cell carcinoma . These patient undergo second collection blood urine sample 3 month post-nephrectomy .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<criteria>Inclusion : Age &gt; 18 year Meets 1 follow criterion : Diagnosis renal cell carcinoma , meet follow criterion : Suitable surgical candidate No clinical pathologic T stage &gt; T2 No clinical pathologic evidence vein and/or lymph node involvement No evidence metastatic disease evaluate abdominal/pelvic CT scan MRI , chest xray chest CT scan , bone scan ( alkaline phosphatase abnormal ) Diagnosis transitional cell carcinoma urothelium Currently undergo Bacille calmettegu√©rin ( BCG ) therapy OR receive prior BCG therapy Healthy participant ( control ) No history carcinoma Exclusion : Previous concurrent malignancy except curatively treat carcinoma situ cervix nonmelanoma skin cancer Serious medical psychiatric illness would preclude study compliance Current participation treatment relate research study within last 30 day Acute illness Bleeding disorder dyscrasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>localize transitional cell cancer renal pelvis ureter</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
</DOC>